Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
David A SallmanAmy E DeZernGuillermo Garcia ManeroDavid P SteensmaGail J RobozMikkael A SekeresThomas CluzeauKendra L SweetAmy F McLemoreKathy L McGrawJohn PuskasLing ZhangJiqiang YaoQianxing MoLisa NardelliNajla H Al AliEric PadronGreg KorbelEyal C AttarHagop M KantarjianJeffrey E LancetPierre FenauxAlan F ListRami S KomrokjiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.